References
- NICE. Health technology appraisal scope document. Newer drugs for adults with epilepsy: London, National Institute for Clinical Excellence, 2002.
- Heaney DC, Begley CE. Economic evaluation of epilepsy treatment: a review of the literature. Epilepsia 2002; 43 (Suppl 4): 10–17.
- Loomes G, McKenzie L. The use of QALYs in health care decision making. Social Science and Medicine 1989; 28: 299–308.
- Selai CE, Smith K, Trimble MR. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. Seizure 1999; 8: 8–13.
- Selai CE, Trimble MR. Adjunctive therapy in epilepsy with new antiepileptic drugs: is it of any value? Seizure 1998; 7: 417–418.
- O’Donoghue MF, Duncan JS, Sander JWAS. The National Hozpital Seizure Severity Scale: a further development of the Chalfont Seizure Severity Scale. Epilepsia 1996; 37: 563–571.
- Kendrick AM, Trimble MR. Repertory grid in the assessment of quality of life in patients with epilepsy: the Quality of Life Assessment Schedule. In Trimble MR, Dodson WE , Eds. Epilepsy and the Quality of Life. New York, Raven Press, 1994.
- EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199–208.
- British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary 44. London, 2002.
- Netten A, Curtis L. Unit costs of health and social care 2002. University of Kent, Canterbury. Personal Social Services Research Unit, 2002.
- The Chartered Institute of Public Finance and Accountancy (CIPFA). The health service financial database and comparative tool, 2001. Institute of Public Finance Limited, Croydon, 2001.
- Dolan P, Gudex C, Kind P, Williams A. A social tariff for Euroqol; results from a UK general population study. Discussion paper 138. University of York, Centre for Health Economics, York, 1995.
- Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Economics 1997; 6: 327–340.
- Briggs AH, Tambour M. The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions. Drug Information Journal 2001; 35: 1455–1468.
- Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost- effectiveness acceptability curves. Health Economics 2001; 10: 779–787.
- Selai C, Kaiser S, Trimble M, Price M. Evaluation of the relationship between epilepsy severity and utility [Abstract] Value in Health 2002; 5: 512–513.
- CareLine Information Centre for Wandsworth, http://www.careline.org.uk. Date accessed: 15 May 2003.
- University College London Hospitals NHS Trust Provider to Provider Tariff 2002–2003, http://www.uclh.org. Date accessed: 15 May 2003.
- NHS Reference Costs 2002, http://www.doh.gov.uk/nhsexec/refcost s.htm.
- OMNILABS (UK) Limited. Directory and price list, October 2000.
- van Hout BA, Gagnon DD, McNulty P, O’Hagan A. The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data – A first approximation. Pharmacoeconomics 2003; 21: 315–326.
- Stavem K, Bjørnæs H, Lossius MI. Properties of the 15D and EQ-5D utility measures in a community sample of people with epilepsy. Epilepsy Research 2001; 44: 179–189.